Background: Studies have suggested that cytokines are crucial mediators in the pathogenesis of Parkinson’s disease (PD). The multifunctional cytokine interleukin (IL)-6 and its single nucleotide polymorphisms (SNPs) were found to have an impact on the development of PD. However, different studies in associations of IL-6 genetic variants with PD showed inconsistent results and it has never been explored in a Taiwanese population. Both IL-1α and IL-8 contribute to the same inflammation pathway. IL-1α genetic polymorphism has an effect on late-onset PD in Taiwan, whereas the associations of IL-8 genetic variants with PD in Taiwan remain to be investigated. Methods: This study examined the frequencies of polymorphisms within the critical promoter areas of the proinflammatory cytokine genes: IL-6 G-174C (rs1800795) and IL-8 A-251T (rs4073) in Taiwanese PD patients compared with age-and gender-matched healthy subjects. Comparisons were also made in genotype and allele frequencies of IL-6 G-174C (rs1800795) and IL-8 A-251T (rs4073) among different populations in previous studies. Results: In total, 1120 subjects, including 509 PD patients (female/male: 259/250) and 511 control subjects (female/male: 252/259), were recruited. We found no statistically significant differences in IL-6 G-174C (rs1800795) or IL-8 A-251T (rs4073) genotypic and allelic distribution between PD and controls, even after being stratified by age at onset and gender. Conclusions: The results did not demonstrate any association of IL-6 G-174C (rs1800795) or IL-8 A-251T (rs4073) with PD in a Taiwanese population. Despite the negative results, this is the first study in associations of IL-6 G-174C (rs1800795) and IL-8 A-251T (rs4073) with PD in Taiwan. The relevance of genetic variants of IL-6 G-174C (rs1800795) or IL-8 A-251T (rs4073) on PD susceptibility warrants further investigation.
Neuromyelitis optica spectrum disorder (NMOSD) is a neuroinflammatory disease caused by aquaporin-4 (AQP4) IgG antibodies, which damage astrocytes and trigger inflammation. Although altered lipid profiles have been observed in various neuroinflammatory diseases, the role of dyslipidemia in NMOSD disease activity remains poorly understood. In this study, we analyzed plasma lipoprotein profiles in 40 patients with NMOSD during relapses, 35 patients with multiple sclerosis (MS) during relapses, and 41 age- and sex-matched healthy controls (HCs). Among 112 lipoprotein components, 38 showed significant alterations in NMOSD patients compared to both MS patients and HCs. These components exhibited consistently lower levels during relapses. Receiver operating characteristic (ROC) analysis identified total apolipoprotein-A2 (Apo-A2; AUC = 0.808), HDL-3-Apo-A2 (AUC = 0.806), HDL-Apo-A2 (AUC = 0.798), VLDL-2-phospholipids (AUC = 0.774), VLDL-3-phospholipids (AUC = 0.769), and VLDL-3-triglycerides (AUC = 0.770) as robust biomarkers for distinguishing NMOSD from HCs, while VLDL-3-phospholipids (AUC = 0.791) and HDL-3-Apo-A2 (AUC = 0.752) effectively differentiated NMOSD from MS. Importantly, HDL-4-Apo-A2 levels negatively correlated with Expanded Disability Status Scale (EDSS) scores (r = -0.321, P = 0.043) and spinal cord lesion length (r = -0.391, P = 0.013) in NMOSD patients. Among 22 NMOSD patients evaluated longitudinally, 36 of the 38 dysregulated lipoprotein components return to normal levels during remission. This study represents the first comprehensive lipidomic analysis in NMOSD, revealing distinct dyslipidemia patterns associated with disease activity and highlighting the potential of lipoprotein profiling as a non-invasive prognostic biomarker.